Momentum Bioscience
Momentum Bioscience is focused on developing rapid tests for bloodstream infection in patients suspected of sepsis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€2.5m | Grant | ||
| Total Funding | 000k | ||
| GBP | 2009 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| % profit margin | (81 %) |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
Developer of technology for targeted single-molecule enrichment of DNA and RNA based in Herlev, Denmark. The company specializes in DNA enrichment, molecular methods and sequence that permit informed research decisions, empowering scientists to sequence any genetic region for the purpose of determining virus integration, excluding unintended CRISPR edits and closing gaps in otherwise inaccessible regions.
Keywords: Blood Testing, Clinical Specimens, Clinical Specimens Test, In Vitro Diagnostic Testing, Infection Detection, Medical Testing Technology, Rapid Detection, Rapid Test, Sepsis, Sepsis Diagnostics.
Tech stack
Investments by Momentum Bioscience
Edit